Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: An open label, noncomparative, double tympanocentesis study

Pediatric Infectious Disease Journal

Volumn 22, Issue 11, 2003, Pages 943-949

  Leibovitz, Eugene ^a   Piglansky, Lolita ^a   Raiz, Simon ^a   Greenberg, David ^a   Hamed, Kamal A ^b   Ledeine, Jean Marie ^b   Press, Joseph ^a   Leiberman, Alberto ^a   Echols, Roger M ^b   Pierce, Phillip F ^b   Jacobs, Michael R ^c   Dagan, Ron ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacterial eradication; Gatifloxacin; Nonresponsive acute otitis media; Recurrent acute otitis media; Relapse; Streptococcus pneumoniae

Indexed keywords

BETA LACTAMASE; GATIFLOXACIN; PENICILLIN G;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM EXAMINATION; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYRINGOTOMY; NEUTROPENIA; OTITIS MEDIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

ACUTE DISEASE; ADMINISTRATION, ORAL; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROQUINOLONES; HUMANS; INFANT; MALE; OTITIS MEDIA; RECURRENCE; TREATMENT OUTCOME;

EID: 10744220407     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000095468.89866.14     Document Type: Article

References (37)

1. Pichichero ME. Recurrent and persistent otitis media. Pediatr Infect Dis J 2000;19:911-16.
2. Faden H. The microbiologic and immunologic basis for recurrent otitis media in children. Eur J Pediatr 2001;160:407-13.
3. Pichichero ME, Pichichero CL. Persistent acute otitis media: I. Causative pathogens. Pediatr Infect Dis J 1995;14:178-83.
4. Faden H, Bernstein J, Brodsky L, et al. Effect of prior antibiotic treatment on middle ear disease in children. Ann Otol Laryngol 1992;101:87-91.
5. Leibovitz E, Raiz S, Piglansly L, et al. Resistance pattern of middle ear fluid isolates in acute otitis media recently treated with antibiotics. Pediatr Infect Dis J 1998;17:643-9.
6. Gehanno P, N'Guyen L, Derriennic M, Pichon F, Goehrs JM, Berche P. Pathogens isolated during treatment failures in otitis. Pediatr Infect Dis J 1998;17:885-90.
7. Loundon N, Roger G, Vu Thien H, Begue P, Garabedian EN. Evolution of the bacteriologic features of persistent otits media compared with acute otitis media; a 15-year study. Arch Otolaryngol Head Neck Surg 1999;125:1134-40.
8. Li WC, Chiu NC, Hsu CH, Lee KS, Hwang HK, Huang FY. Pathogens in the middle ear effusion of children with persistent otitis media: implications of drug resistance and complications. J Microbiol Immunol Infect 2001;34:190-4.
9. Block SL. Strategies for dealing with amoxicillin failure in acute otitis media. Arch Fam Med 1999;8:68-87.
10. Wald ER, Mason EO Jr, Bradley JS, Barson WJ, Kaplan SL and the US Pediatric Multicenter Pneumococcal Surveillance Group. Acute otitis media caused by Streptococcus pneumoniae in children's hospitals between 1994 and 1997. Pediatr Infect Dis J 2001;20:34-9.
11. Dowell SF, Butler JC, Giebink SG, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance: a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999;18:1-9.
12. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis J 1996;15:980-5.
13. Dagan R, Abramson O, Leibovitz E, et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997;176:1253-9.
14. Dagan R. Can the choice of antibiotics for therapy of acute otitis media be logical? Eur J Clin Microbiol Infect Dis 1998;17:1-5.
15. Dagan R, Johnson C, McLinn S et al. Bacteriological and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000;19:95-104.
16. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J 2001;20: 829-37.
17. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic efficacy of a three-day intramuscular ceftriaxone regimen in nonresponsive acute otitis media. Pediatr Infect Dis J 1998;17: 1126-31.
18. Leibovitz E, Piglansky L, Raiz S, et al. The bacteriologic efficacy of 1-day versus 3-day intramuscular ceftriaxone in the treatment of non-responsive acute otitis media. Pediatr Infect Dis J 2000;19:1040-5.
19. Zhanel G, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory tract infections. Drugs 2002;62:13-59.
20. Austrian R. The quellung reaction, a neglected microbiologic technique. Mt Sinai J Med 1976;43:699-709.
21. National Committee for Clinical Laboratory Standards. Methods for dilutional antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard M7-A4. Wayne, PA: National Committee for Clinical Laboratory Standards, 1995.
22. National Committee for Clinical Laboratory Standards MIC testing supplemental tables (M100-S10). Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.
23. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-39.
24. Gough A, Barsoum NJ, Mitchell L, McGuire EJ, de la Iglesias FA. Juvenile canine drug-induced arthropathy: clinicopathologic studies on articular lesions caused by oxolinic and pipemidic acids. Toxicol Appl Pharmacol 1979;51:177-87.
25. Schaad UB, Stoupis C, Wedgwood J, Tschaeppeler H, Vock P. Clinical, radiologic and magnetic resonance monitoring for skeletal toxicity in children with cystic fibrosis receiving a three-month course of ciprofloxacin. Pediatr Infect Dis J 1991;10:723-9.
26. Burkhardt JE, Walterspiel JN, Schaad UB. Quinolone arthropathy in animals versus children. Clin Infect Dis 1997; 25:1196-204.
27. Chysky V, Kapila K, Hullmann R, Arcieri G, Schacht P, Echols R. Safety of ciprofloxacin in children: worldwide clinical experience based on compassionate use: emphasis on joint evaluation. Infection 1991;19:289-96.
28. Hampel B, Hullmann R, Schmidt H. Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use: safety report. Pediatr Infect Dis J 1997;16:127-9.
29. Perry CM, Ormrod D, Hurst M, Onrust SV. Gatifloxacin: a review of its use in the management of bacterial infections. Drugs 2002;62:169-207.
30. Hoelmann DB, Lin G, Jacobs MR, Appelbaum PC. Antipneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J Antimicrob Chemother 1999;43:645-9.
31. Fukuda H, Hiramatsu K. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:410-12.
32. Fogarty C, Dowell ME, Ellison WT, et al. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs. ceftriaxone/clarithromycin. J Respir Dis 1999;20(Suppl): S60-9.
33. Ramirez JA, Nguyen TH, Tellier G, et al. Treating community-acquired pneumonia with once-daily gatifloxacin vs. twice-daily clarithromycin. J Respir Dis 1999;20(Suppl): S40-8.
34. Leibovitz E, Greenberg D, Piglansky L, et al. Recurrent acute otitis media occurring within one month from completion of antibiotic therapy: relationship to the original pathogen. Pediatr Infect Dis J 2003;22:209-15.
35. Urban C, Rahman N, Zhao X, et al. Fluoroquinolone-resistant Streptococcus pneumoniae associated with levofloxacin therapy. J Infect Dis 2001;184:794-8.
36. Ho PL, Tsang KW, Kwok TK, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001;32:701-7.
37. Quale J, Landman D, Ravishankar J, Flores C, Bratu S. Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep. Emerg Infect Dis 2002;8: 594-7.